SGLT-2 inhibitors beyond diabetes: a new frontier in cancer treatment

Basit Öğe Kaydı
dc.authorid0009-0003-9411-2846
dc.authorid0000-0003-4056-1673
dc.contributor.authorNakhaei, Ali
dc.contributor.authorDelavar, Kiana
dc.contributor.authorAzim, Azin Sadat
dc.contributor.authorAfshari, Sadaf
dc.contributor.authorMohtashami, Alireza
dc.contributor.authorJalili-Nik, Mohammad
dc.contributor.authorJalali, Mahsa
dc.date.accessioned2026-02-03T12:02:45Z
dc.date.available2026-02-03T12:02:45Z
dc.date.issued2025
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractSodium-glucose co-transporter 2 (SGLT-2) inhibitors, a new class of antidiabetic medications including canagliflozin, dapagliflozin, ipragliflozin, and empagliflozin, recently came to light as possible anti-cancer therapeutics. The confirmed presence of SGLT-2 in many cancer cell lines further substantiates their potential as therapeutic targets. Because many cancer cells change their metabolism to become more glucose-dependent, blocking glucose absorption with SGLT-2 inhibitors is an intriguing anti-cancer therapy. In addition to their physiological function in renal proximal tubules, SGLT-2 has been identified in specific tumor cells. Clinical trials have shown that SGLT-2 inhibitors are safe and well-tolerated in individuals with diabetes and heart failure. Significantly, these medicines demonstrate antiproliferative effects across multiple cancer types, as substantiated by both in vitro and in vivo models, frequently via mechanisms that are independent of SGLT-2 itself. They seem to regulate a diverse array of intracellular and extracellular signaling pathways, encompassing those associated with microRNAs, AMPK, ERK, DNA and RNA metabolism, ATP homeostasis, and mitochondrial function. These data collectively underscore the potential of SGLT-2 inhibitors in clinical oncology and elucidate the processes driving their anti-cancer efficacy.
dc.identifier.doi10.1016/j.diabres.2025.112925
dc.identifier.issn0168-8227
dc.identifier.issn1872-8227
dc.identifier.pmid41016479
dc.identifier.scopus2-s2.0-105017224790
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1016/j.diabres.2025.112925
dc.identifier.urihttps://hdl.handle.net/20.500.12428/34862
dc.identifier.volume229
dc.identifier.wosWOS:001587391500001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Ireland Ltd
dc.relation.ispartofDiabetes Research and Clinical Practice
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20260130
dc.subjectSGLT-2 inhibitors
dc.subjectDapagliflozin
dc.subjectEmpagliflozin
dc.subjectCanagliflozin
dc.subjectCancer
dc.titleSGLT-2 inhibitors beyond diabetes: a new frontier in cancer treatment
dc.typeReview

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu